Presenting author

Christine zu Eulenburg

1 presentation

• T26. A phase 2 clinical trial exploring efficacy and safety of the vasopressin V1b antagonist BH-200, a treatment for MDD, evaluating the performance of a genetic classification tool to identify a subset of patients with larger improvement

  2026 ASCP Annual Meeting